IRD — Opus Genetics, Inc.
NASDAQ · Healthcare · Biotechnology
$3.94
+$0.11 (+2.86%)
Opus Genetics, Inc. (IRD) is a biotechnology company listed on NASDAQ. It is led by George Magrath M.B.A., M.D., M.S., based in 8 Davis Drive, Durham, NC, United States, 27709, with about 18 employees. Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
Latest reported IRD revenue for 2025-09-30 was $3.1M. Net income was -$17.5M. Revenue was up 6.8% from 2025-06-30 to 2025-09-30. IRD currently screens at market cap $35.7M.
Use this IRD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the IRD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the IRD SEC filings page. Lician reads the product cache first so this HTML stays unique to Opus Genetics, Inc. even when a live quote feed is slow.
About Opus Genetics, Inc.
Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of inherited retinal diseases (IRDs). It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations; OPGx-RDH12 that is designed to restore protein expression and halt functional deterioration in patients with retinal dystrophy caused by mutations in the retinal dehydrogenase gene; OPGx-MERTK, an AAV vector for the treatment of MERTK IRD; OPGx-NMNAT1, a gene augmentation therapy designed to halt functional deterioration in pediatric patients with retinal degenerative disease caused by mutations in the nicotinamide mononucleotide adenylyltransferase 1 gene; and OPGx-CNGB1, an AAV gene therapy for retinitis pigmentosa due to mutations in the CNGB1 gene. In addition, it develops Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as for the treatment of presbyopia and dim light or night vision disturbances; and APX3330, a small-molecule inhibitor of Ref-1 for the treatment of diabetic retinopathy. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Durham, North Carolina.
IRD Key Statistics
Market Cap
$35.67M
Volume
1.49M
Previous Close
$4.03
Day Range
$4.04 – $4.41
EPS
-$2.15
Revenue
$10.99M
Net Income
-$57.53M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-42.3%
Profit Margin
-523.4%
Employees
18
IRD Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $10.99M | $19.05M | $39.85M | $589.00K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$57.53M | -$9.99M | $17.89M | -$56.69M |
| EPS (Diluted) | -$2.15 | -$0.46 | $0.87 | -$3.82 |
Total Assets
$36.86M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$30.32M
Operating Cash Flow
-$25.58M
Free Cash Flow
$0.00
Opus Genetics, Inc. Company Information
- CEO & Director
- George Magrath M.B.A., M.D., M.S.
- Headquarters
- 8 Davis Drive, Durham, NC, United States, 27709
- Website
- opusgtx.com
- Phone
- 984 884 6030
- IPO / Founded
- 2005-05-23
- Sector
- Healthcare
- Industry
- Biotechnology